1. Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study. Issue 11 (16th July 2018) Authors: Waked, Imam; Esmat, Gamal; Fouad, Rabab; Allam, Naglaa; Hassany, Mohamed; Mohey, Mohammad; Shiha, Gamal; Soliman, Reham; Qaqish, Roula B.; Hall, Coleen; Alami, Negar N.; Kopecky‐Bromberg, Sarah; Mobashery, Niloufar Journal: Journal of medical virology Issue: Volume 90:Issue 11(2018) Page Start: 1739 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. (September 2016) Authors: Waked, Imam; Shiha, Gamal; Qaqish, Roula B; Esmat, Gamal; Yosry, Ayman; Hassany, Mohamed; Soliman, Reham; Mohey, Mohammad A; Allam, Naglaa; Zayed, Naglaa; Asselah, Tarik; Hall, Coleen; Redman, Rebecca; Mobashery, Niloufar; Doss, Wahid Journal: Lancet gastroenterology and hepatology Issue: Volume 1:Number 1(2016) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗